• Home

  • Documents

  • Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
23

Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

Embed Size (px)

DESCRIPTION

- PowerPoint PPT Presentation

Citation preview

Page 1: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 2: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 3: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 4: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 5: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 6: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 7: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 8: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 9: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 10: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 11: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 12: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 13: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 14: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 15: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 16: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 17: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 18: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 19: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 20: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 21: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 22: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 23: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

Oral Anti-Diabetic Agents-Review and Updates€¦ · Keywords: Antidiabetic drugs; DPP-4 inhibitors; metformin; oral hypoglycemic agents (OHA); saroglitazar; SGLT 2 inhibitors; sulphonylureas

Oral Anti-Diabetic Agents-Review and Updates€¦ · Keywords: Antidiabetic drugs; DPP-4 inhibitors; metformin; oral hypoglycemic agents (OHA); saroglitazar; SGLT 2 inhibitors; sulphonylureas

Documents
An Update On Dpp 4 Inhibitors In The Management Of Type 2 Diabetes

An Update On Dpp 4 Inhibitors In The Management Of Type 2 Diabetes

Education
A REVIEW: DIPEPTIDYLPEPTIDASE-4 INHIBITORS (GLIPTINS) · possible side effects. However, since clinical trials showed the opposite, the latest DPP-4 inhibitors have a long-lasting

A REVIEW: DIPEPTIDYLPEPTIDASE-4 INHIBITORS (GLIPTINS) · possible side effects. However, since clinical trials showed the opposite, the latest DPP-4 inhibitors have a long-lasting

Documents
The effects of DPP-4 inhibitors on vascular endothelial function in … · 2016. 5. 4. · The effects of DPP-4 inhibitors on vascular endothelial function in diabetes A thesis submitted

The effects of DPP-4 inhibitors on vascular endothelial function in … · 2016. 5. 4. · The effects of DPP-4 inhibitors on vascular endothelial function in diabetes A thesis submitted

Documents
PharmEvo Diabetes & DPP-4 Inhibitors Workshop 2013

PharmEvo Diabetes & DPP-4 Inhibitors Workshop 2013

Documents
Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

Documents
Dipeptidyl peptidase 4 (DPP-4) inhibitors and ......Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over

Dipeptidyl peptidase 4 (DPP-4) inhibitors and ......Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over

Documents
Dr Brandon Orr-Walker - GP CME North/Sat_Plenary_1215_Orr... · 2018-06-09 · Side Effects: GLP-1 Receptor Agonists and DPP-4 Inhibitors GLP-1 Receptor Agonists DPP-4 Inhibitors

Dr Brandon Orr-Walker - GP CME North/Sat_Plenary_1215_Orr... · 2018-06-09 · Side Effects: GLP-1 Receptor Agonists and DPP-4 Inhibitors GLP-1 Receptor Agonists DPP-4 Inhibitors

Documents
1 The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

1 The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

Documents
Diabetes Mellitus: Treatment Challenges and the …...degradation and DPP-IV inhibitors (sitagliptin) were cardiovascular mortality. A meta-analysis published in developed [34, 35]

Diabetes Mellitus: Treatment Challenges and the …...degradation and DPP-IV inhibitors (sitagliptin) were cardiovascular mortality. A meta-analysis published in developed [34, 35]

Documents
Copd n comorbidities

Copd n comorbidities

Health & Medicine
Ra comorbidities

Ra comorbidities

Health & Medicine
Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

Documents
CA D TH ISSUES IN EMERGING HEA LT H TECHNOLO GIES...CV outcomes and all drugs in the following classes: DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists. Methodological

CA D TH ISSUES IN EMERGING HEA LT H TECHNOLO GIES...CV outcomes and all drugs in the following classes: DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists. Methodological

Documents
Incretinas, Incretinomiméticos, Inhibidores de DPP IV ... · Incretinas, Incretinomiméticos, Inhibidores de DPP IV – 1er parte Incretins, Incretinmimetics, Inhibitors ... dicho

Incretinas, Incretinomiméticos, Inhibidores de DPP IV ... · Incretinas, Incretinomiméticos, Inhibidores de DPP IV – 1er parte Incretins, Incretinmimetics, Inhibitors ... dicho

Documents
Side Effects of · 2018-04-29 · Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018

Side Effects of · 2018-04-29 · Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018

Documents
Normal Fuel Metabolism - Amazon Web Servicesenp-network.s3.amazonaws.com/NPA_Syracuse/file/... · • DDP-4 inhibitors: 4 medications plus 7 combinations Dipeptidyl peptidase-4 (DPP-4)

Normal Fuel Metabolism - Amazon Web Servicesenp-network.s3.amazonaws.com/NPA_Syracuse/file/... · • DDP-4 inhibitors: 4 medications plus 7 combinations Dipeptidyl peptidase-4 (DPP-4)

Documents
 · Web viewThree dipeptidyl-peptidase 4 (DPP-4) inhibitors are currently available in the United States: sitagliptin, saxagliptin and linagliptin. None of the DPP-4 inhibitors are

 · Web viewThree dipeptidyl-peptidase 4 (DPP-4) inhibitors are currently available in the United States: sitagliptin, saxagliptin and linagliptin. None of the DPP-4 inhibitors are

Documents
2018 ANNUAL TREND REPORT...As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors due to their ability to reduce

2018 ANNUAL TREND REPORT...As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors due to their ability to reduce

Documents
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review … · 2019. 7. 30. · Review Article DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus:

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review … · 2019. 7. 30. · Review Article DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus:

Documents
Utah Medicaid Pharmacy and Therapeutics Committee Drug Class … ·  · 2019-10-30Introduction: Dipeptidylpeptidase-4 inhibitors (DPP-4i) are oral medications indicated for adults

Utah Medicaid Pharmacy and Therapeutics Committee Drug Class … ·  · 2019-10-30Introduction: Dipeptidylpeptidase-4 inhibitors (DPP-4i) are oral medications indicated for adults

Documents
Janos Fischer-Serendipitous Target-based Drug Discovery · Drug therapy of type 2 of diabetes with DPP-4 inhibitors 2001 sitagliptin : pioneer DPP-4 inhibitor (QD) 1998 vildagliptin

Janos Fischer-Serendipitous Target-based Drug Discovery · Drug therapy of type 2 of diabetes with DPP-4 inhibitors 2001 sitagliptin : pioneer DPP-4 inhibitor (QD) 1998 vildagliptin

Documents
Medication Management in Diabeteswadepage.org/files/2019Conf/WADE_DM meds_Emerging_Newsome_Updated.pdfAdministration Subcutaneous Oral Gallwitz B. EurEndocr Dis 2006:43-46. DPP-4 Inhibitors:

Medication Management in Diabeteswadepage.org/files/2019Conf/WADE_DM meds_Emerging_Newsome_Updated.pdfAdministration Subcutaneous Oral Gallwitz B. EurEndocr Dis 2006:43-46. DPP-4 Inhibitors:

Documents
A New Therapy of Type 2 Diabetes: DPP-4 Inhibitorscdn.intechweb.org/pdfs/21462.pdf1 A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors Tatjana Ábel National Health Center Hungary

A New Therapy of Type 2 Diabetes: DPP-4 Inhibitorscdn.intechweb.org/pdfs/21462.pdf1 A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors Tatjana Ábel National Health Center Hungary

Documents
The effects of DPP-4 inhibitors on vascular endothelial ...researchbank.rmit.edu.au/view/rmit:161445/Salheen.pdf · The effects of DPP-4 inhibitors on vascular endothelial function

The effects of DPP-4 inhibitors on vascular endothelial ...researchbank.rmit.edu.au/view/rmit:161445/Salheen.pdf · The effects of DPP-4 inhibitors on vascular endothelial function

Documents
PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH TYPE 2 …ijsit.com/admin/ijsit_files/PHARMACOLOGICAL MANAGEMENT OF... · 2019-03-02 · f) DPP-4 inhibitors: The DPP-4 Inhibitors is not

PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH TYPE 2 …ijsit.com/admin/ijsit_files/PHARMACOLOGICAL MANAGEMENT OF... · 2019-03-02 · f) DPP-4 inhibitors: The DPP-4 Inhibitors is not

Documents
Dipeptidyl Petidase-4 (DPP-4) Inhibitors - Utah … currently available DPP-4 inhibitors in the US include sitagliptin (Januvia), saxagliptin (Onglyza), linaglitin (Tradjenta), and

Dipeptidyl Petidase-4 (DPP-4) Inhibitors - Utah … currently available DPP-4 inhibitors in the US include sitagliptin (Januvia), saxagliptin (Onglyza), linaglitin (Tradjenta), and

Documents
Oral Antidiabetic Agents-Review and Updates€¦ · 16 Keywords: Antidiabetic drugs, DPP-4 inhibitors, metformin, oral hypoglycemic agents (OHA), saroglitazar, SGLT 2 17 inhibitors,

Oral Antidiabetic Agents-Review and Updates€¦ · 16 Keywords: Antidiabetic drugs, DPP-4 inhibitors, metformin, oral hypoglycemic agents (OHA), saroglitazar, SGLT 2 17 inhibitors,

Documents
DPP-4 Inhibitors: ‘GLIPTINS’ - FLAME · 2019-04-21 · MECHANISM OF ACTION u Dipeptidyl peptidase 4 (DPP-4) acts to inhibit incretins GIP and GLP-1 at the pancreatic islets u

DPP-4 Inhibitors: ‘GLIPTINS’ - FLAME · 2019-04-21 · MECHANISM OF ACTION u Dipeptidyl peptidase 4 (DPP-4) acts to inhibit incretins GIP and GLP-1 at the pancreatic islets u

Documents
Diabetes Workshop: Developing Strategies for the Most ...primarycareinternalmedicine2018.com/uploads/1/2/2/... · Clinical use of DPP-4 inhibitors • Tablet, but expensive • HbA1c

Diabetes Workshop: Developing Strategies for the Most ...primarycareinternalmedicine2018.com/uploads/1/2/2/... · Clinical use of DPP-4 inhibitors • Tablet, but expensive • HbA1c

Documents